Evidence map›Paper›PMID 42542590›Full record

ArticleiScience2026

The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma.

Ayako Kamiunten, Daisuke Morishita, Takuro Kameda, Midori Sugiyama, Shunsuke Ebara, Yasunori Kogure, Akio Mizutani, Takaharu Hirayama, Tomohiro Kawamoto, Yotaro Ochi and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Ayako KamiuntenDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Daisuke MorishitaChordia Therapeutics Inc., Fujisawa, Kanagawa 251-0012, Japan.
Takuro KamedaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Midori SugiyamaChordia Therapeutics Inc., Fujisawa, Kanagawa 251-0012, Japan.
Shunsuke EbaraChordia Therapeutics Inc., Fujisawa, Kanagawa 251-0012, Japan.
Yasunori KogureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Akio MizutaniChordia Therapeutics Inc., Fujisawa, Kanagawa 251-0012, Japan.
Takaharu HirayamaAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Tomohiro KawamotoAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Yotaro OchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606-8315, Japan.
Kotaro ShideDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Hidekazu TokuharaAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Toshio TanakaAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Hiroshi BannoAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Yasuyoshi ArikawaChordia Therapeutics Inc., Fujisawa, Kanagawa 251-0012, Japan.
Takamitsu MaruAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Hideyuki OkiAxcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa 251-0012, Japan.
Akinori YodaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606-8315, Japan.
Yuki TahiraDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Ryoma IkedaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Kengo MatsumotoDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Masayoshi KarasawaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Keiichi AkizukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Masaaki SekineDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Haruko ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Tomonori HidakaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Yoko KubukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Hideki YamaguchiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.
Hiroo HasegawaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Jun-Ichirou YasunagaDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto 860-8556, Japan.
Masao MatsuokaDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto 860-8556, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences of Kagoshima University, Kagoshima, Kagoshima 890-8544, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences of Kagoshima University, Kagoshima, Kagoshima 890-8544, Japan.
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606-8315, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki 889-1692, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T cell leukemia/lymphoma (ATL) is an aggressive T cell malignancy with poor prognosis. Recurrent genetic alterations in T cell receptor (TCR) signaling components, including

Indexed as

adult T cell leukemia/lymphomaMALT1 inhibitor

Identifiers

PMID42542590
PMCPMC13427568

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.